Medical Degree , Medical

BS , Finance

Dr. Lindsay Rosenwald is one of the most prolific entrepreneurs in the field of biotechnology.  His myriad contributions to that industry are centered around of the Paramount Group of Companies, which he is the Founder and Chairman of.  These ventures range from Paramount Corporate Development, a firm that helps to facilitate and coordinate drug and corporate development and development activities for Paramount's myriad portfolio companies, to Paramount BioSciences, a global pharmaceutical development and healthcare investment company specializing in the conception, nurturing, and support of budding biotechnology companies.  Also providing support for Paramount and its various portfolio companies is Paramount BioCapital, a registered broker-dealer with Financial Industry Regulatory Authority, Inc., or FINRA.  Paramount BioCapital raises capital and support for Paramount's portfolio companies and has raised about $950,000,000 for these establishments since its inception in 1991.
After graduating from Abington High School in southeastern Pennsylvania in 1973, Dr. Rosenwald attended Pennsylvania State University as a Finance major.  He graduated in 1977 as a member of Beta Gamma Sigma, a business school honor society, and moved on to Temple University's School of Medicine.  After graduating from Temple in 1983, Dr. Rosenwald took an internship at Abington Medical Hospital and remained in private medical practice until 1986.  At that time, he moved to Wall Street to serve as a physician/financial analyst, a specialized combination of fields which very few boasted at that time.  
In 1991, Dr. Rosenwald formed Paramount BioCapital, and in the 19 years since then has revolutionized the field medical research.  One of his portfolio companies hold the record for a drug, Arsenic Trioxide, moving most quickly from development to Food & Drug Administration approval.  Cougar Biotechnology, another company founded by Dr. Rosenwald, was purchased by Johnson & Johnson in 2009 based solely on abiraterone acetate.  This drug was not yet in phase III clinical trials for its application in prostate cancer treatment and therapy, but was so promising that Johnson & Johnson bid & purchased the company in a "short-term merger" for approximately $1 billion.  Abiraterone acetate is also notable as having been based on a Traditional Chinese Medicine (TCM) practice.  In addition to his activities which have provided capital and funding to many portfolio companies, Dr. Rosenwald also started the Rosenwald Foundation, a nonprofit organization which has provided millions of dollars to support various scientific and medical education institutions.  These funds and grants provide the groundbreaking scientists and researchers of today with the resources they need to forge the advancement of medicine and biotechnology into the future.
Dr. Lindsay Rosenwald's nearly 20-year track record in the arenas of biotechnology, pharmaceutics, biomedicine, and finance have placed him at the forefront of cutting-edge advancements and development.  The singular combination of fields he studied in - medicine and finance - places him in a rare and unique position to identify opportunities to broaden the borders of high-tech medicine and support those researchers that pioneer on those frontiers.  With a rich and diverse background  in an incredibly specialized industry, Dr. Rosenwald's prolific achievements are unmatched in the industry.